MDMA in Borderline Personality Disorder (MDMA in BPD)

This open-label trial (n=10) will investigate the effects of a single dose of MDMA on social cognition in adults with Borderline Personality Disorder (BPD).

Conducted by Yale University and led by Dr. Sarah Fineberg, the study aims to assess changes in self-reported sociability and emotion recognition following MDMA administration.

Participants must be unmedicated, aged 18-60, and diagnosed with BPD, with strict exclusion criteria to ensure safety. The study will measure sociability using a visual analogue scale and evaluate changes in facial emotion recognition accuracy. Data collection will conclude in June 2026.

Topic Borderline
Compound MDMA
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 February 2025
End date 01 June 2026
Phase Phase II
Design Open
Type Interventional
Generation First
Participants 10
Sex All
Age 18- 60
Therapy No

Trial Details

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Trial Number NCT06683014

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.